Inactive Instrument

Press Releases OUTLOOK THERAPEUTICS, INC. Nasdaq

Equities

US69012T1079

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	12/06	AQ
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	11/06	AQ
European Biosimilar Regulatory Update	10/06	AQ
Corporate Presentation: June 2024	06/06	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	29/05	AQ
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	28/05	AQ
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	16/05	AQ
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	13/05	AQ
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	09/05	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	02/05	AQ
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04	AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	16/04	AQ
Corporate Presentation: March 2024	29/03	PU
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	25/03	AQ
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03	AQ
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	19/03	AQ
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split	13/03	AQ
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	12/03	AQ
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	15/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OUTLOOK THERAPEUTICS, INC. Nasdaq

Equities

US69012T1079

Press Releases

Filters